GlassScriptPhysician profile
John D Morgan
NPI 1679634943
$10,788.93
in general payments reported to CMS, 2019-2025
32 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,163 · 2020: $1,061 · 2021: $252 · 2022: $1,543 · 2023: $1,520 · 2024: $2,387 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,769.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,104.76 | 2019-2025 | |
| Pfizer INC. | $1,646.69 | 2019-2025 | |
| Amgen INC. | $1,033.46 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Ani Pharmaceuticals, INC. | $975.99 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $789.95 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $668.18 | 2019-2025 | Saphnelo |
| Novo Nordisk INC | $327.48 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Biotech, INC. | $308.69 | 2019-2023 | Simponi Aria, Remicade, Stelara |
| Novartis Pharmaceuticals Corporation | $273.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $196.71 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $189.61 | 2019 | |
| Genentech USA, INC. | $186.73 | 2019 | |
| Lilly USA, LLC | $129.21 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $114.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.41 | 2019-2023 | Cyltezo, Tradjenta, Synjardy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $102.35 | 2020 | |
| Astellas Pharma US INC | $97.91 | 2019 | |
| Abbott Laboratories | $77.60 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Genzyme Corporation | $58.24 | 2023 | |
| Aurinia Pharma U.S., INC. | $54.53 | 2023-2024 | Lupkynis |
| Dexcom, INC. | $50.87 | 2024 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $50.59 | 2019 | |
| Horizon Therapeutics Plc | $49.45 | 2019-2023 | Krystexxa |
| Ucb, INC. | $38.83 | 2019-2025 | Bimzelx |
| Janssen Pharmaceuticals, INC | $35.15 | 2019-2020 | |
| Atland Pharmaceuticals, LLC | $28.11 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Fresenius Kabi USA, LLC | $21.50 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.39 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $17.68 | 2024 | Korlym |
| Celgene Corporation | $15.15 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.61 | 2022 | |
| Organon LLC | $9.61 | 2023-2024 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.